Figures & data
Figure 1. Study design
![Figure 1. Study design](/cms/asset/407b8080-2a13-4881-91b7-3ed066085be8/ierv_a_1321990_f0001_oc.jpg)
Table 1. Demographic characteristics (total vaccinated cohort)
Figure 2. Participant Flow Diagram
![Figure 2. Participant Flow Diagram](/cms/asset/8d3c1e0f-b164-430d-833c-8af67576ef5d/ierv_a_1321990_f0002_b.gif)
Table 2. Immunogenicity assessed by GSK 22F ELISA for antipneumococcal antibodies and anti-protein D ELISA (ATP cohort for immunogenicity)
Table 3. Functional immune response assessed by opsonophagocytic activity assay (ATP cohort for immunogenicity)
Figure 3. Kinetics of anti-pneumococcal antibody GMCs (ATP cohort for immunogenicity)
![Figure 3. Kinetics of anti-pneumococcal antibody GMCs (ATP cohort for immunogenicity)](/cms/asset/2cb47cde-31de-4090-81c4-5b78ba1331f0/ierv_a_1321990_f0003_c.jpg)
Figure 4. Kinetics of anti-pneumococcal OPA GMTs (ATP cohort for immunogenicity)
![Figure 4. Kinetics of anti-pneumococcal OPA GMTs (ATP cohort for immunogenicity)](/cms/asset/a0c5735c-8c76-4547-8465-21248802f257/ierv_a_1321990_f0004_c.jpg)
Figure 5. Solicited local and general symptoms (overall per dose; total vaccinated cohort)
![Figure 5. Solicited local and general symptoms (overall per dose; total vaccinated cohort)](/cms/asset/68c9e623-c2a0-4b85-a36a-54fdadaa3e96/ierv_a_1321990_f0005_c.jpg)